The purpose of this study was to explore the neuroprotective role of
swertiamarin on neuro-
inflammation, and analyzed its potential mechanism by proteomics. We used LPS to induce a inflammatory model on BV-2 cells, then 10, 25, 50 μg/mL
swertiamarin was used to treat the LPS pretreated BV-2 cells. We used ELISA to detect the effect of
swertiamarin on the expression of
inflammation related indicators such as IL-1β,
il-6,
IL-18 and TNF-α. The proteomics based on TMT-LC-MS/MS analysis was performed to explore the anti-inflammatory effects of
swertiamarin by bioinformatics analysis. We found swertiamain was able to inhibit pro-inflammatory
cytokines secretion in a does dependent manner, including IL-1β,
IL-6,
IL-18 and TNF-α. These results were further verified by western blot. The proteomics analysis results suggested that the potential bioprocessings which regulated by
swertiamarin mainly involved in cellular response to
carbon monoxide, strand displacement, palmitoleoyltransferase activity, D2
dopamine receptor binding,
RNA polymerase II transcription cofactor activity. The present study may provide a promising approach to treat and prevent neuro-
inflammation diseases. It is preliminarily indicated that
swertiamarin will play an important role in clinical anti-
neuroinflammation process in the future.